Topical therapy in the treatment of actinic keratosis and basal cell carcinoma.
Marissa Newman, Jeffrey M Weinberg
Abstract
Marissa Newman, Jeffrey M Weinberg
Abstract
Actinic keratosis (AK) is an evolving malignant cutaneous neoplasm. AK also is known as solar keratosis and squamous cell carcinoma (SCC) in situ, either solar keratotic type or keratinocytic intraepidermal neoplasia. AKs can be treated with destructive or topical therapies. This article reviews current and evolving topical therapeutic options for AKs, several of which have been shown to offer substantial benefit in the alleviation of these lesions. The topical therapies include 5-fluorouracil (5-FU), diclofenac sodium, colchicine, retinoids, and imiquimod. Topical treatment of basal cell carcinoma (BCC) with imiquimod also will be discussed.
OpenAlex reports 23 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Actinic keratosis (AK) is an evolving malignant cutaneous neoplasm. AK also is known as solar keratosis and squamous cell carcinoma (SCC) in situ, either solar keratotic type or keratinocytic intraepidermal neoplasia. AKs can be treated with destructive or topical therapies. This article reviews current and evolving topical therapeutic options for AKs, several of which have been shown to offer substantial benefit in the alleviation of these lesions. The topical therapies include 5-fluorouracil (5-FU), diclofenac sodium, colchicine, retinoids, and imiquimod. Topical treatment of basal cell carcinoma (BCC) with imiquimod also will be discussed.
Key concepts: Actinic keratosis, Imiquimod, Medicine, Dermatology, Basal cell carcinoma, Keratosis, Basal cell, Fluorouracil